---
id: 112
title: Pseudomonas aeruginosa Management
category: organisms
subcategory: gram_negative_rods
tags: [Pseudomonas, antipseudomonal, MDR, cystic-fibrosis, biofilm]
difficulty: medium
---

## Question

How is *Pseudomonas aeruginosa* treated? Use the **"Antipseudomonal β-Lactam + Consider Combination Therapy (Severe/MDR)"** framework.

## Answer

### **Antipseudomonal Agents:**

**β-Lactams (Backbone):**
- **Cefepime** 2g IV q8h
- **Piperacillin-tazobactam** 4.5g IV q6h (extended infusion)
- **Meropenem** 1g IV q8h (or 2g q8h for severe)
- **Ceftazidime** 2g IV q8h
- **Ceftolozane-tazobactam** 1.5g IV q8h (MDR)
- **Ceftazidime-avibactam** 2.5g IV q8h (MDR, metallo-β-lactamase-negative)

**Fluoroquinolones:**
- **Ciprofloxacin** 400mg IV q8h (or 750mg PO BID)
- **Levofloxacin** 750mg IV/PO daily

**Aminoglycosides:**
- **Tobramycin** 5-7 mg/kg IV daily
- **Amikacin** 15-20 mg/kg IV daily

**Polymyxins (Last Resort):**
- **Colistin** (polymyxin E) 5 mg/kg loading → 2.5 mg/kg IV q12h

### **Treatment by Clinical Scenario:**

| Scenario | Empiric Therapy | Duration | Notes |
|----------|----------------|----------|-------|
| **Pneumonia (non-severe)** | **Cefepime 2g IV q8h** OR **pip-tazo 4.5g IV q6h** | **7-10 days** | Monotherapy acceptable |
| **Pneumonia (severe/ICU)** | **Cefepime + tobramycin** OR **pip-tazo + ciprofloxacin** | **7-14 days** | Combination therapy for severe |
| **Bacteremia (source controlled)** | **Cefepime** OR **pip-tazo** | **7-14 days** | Monotherapy if susceptible |
| **Bacteremia (no source control)** | **Cefepime + tobramycin** | **14 days** | Combination therapy |
| **UTI (uncomplicated)** | **Ciprofloxacin 500mg PO BID** | **7 days** | Oral therapy adequate |
| **MDR/Resistant** | **Ceftolozane-tazobactam** OR **ceftazidime-avibactam** ± aminoglycoside | **14-21 days** | ID consultation |

### **Combination Therapy Indications:**
- **Severe infections** (septic shock, ventilated pneumonia)
- **Bacteremia without source control**
- **Neutropenic fever** (high-risk)
- **MDR *Pseudomonas***
- **Cystic fibrosis** (chronic colonization)

## Key Points

### **Resistance Mechanisms:**
- **Efflux pumps** (remove antibiotics from cell)
- **Porin mutations** (OprD loss → carbapenem resistance)
- **β-lactamases** (AmpC, metallo-β-lactamases)
- **Biofilm formation** (chronic infections, CF)

### **MDR *Pseudomonas* Definition:**
- Resistant to ≥3 antibiotic classes (β-lactams, fluoroquinolones, aminoglycosides)

### **Cystic Fibrosis Considerations:**
- **Chronic colonization** common
- **Higher doses** often required (increased clearance)
- **Combination therapy** standard (β-lactam + aminoglycoside OR fluoroquinolone)
- **Inhaled antibiotics** for maintenance (tobramycin, aztreonam)

### **New Agents for MDR:**
- **Ceftolozane-tazobactam:** Active against many MDR *Pseudomonas* (not MBL)
- **Ceftazidime-avibactam:** Active against KPC, AmpC, ESBL (not MBL)
- **Cefiderocol:** Active against MBL-producing *Pseudomonas*
- **Imipenem-relebactam:** Active against many MDR strains

### **Clinical Pearls:**
- **Monotherapy adequate** for non-severe, susceptible infections
- **Combination therapy** for severe, bacteremia without source control, MDR
- **Cefepime or pip-tazo** first-line empiric therapy
- **Ceftolozane-tazobactam** for MDR (if not MBL)
- **Avoid monotherapy with fluoroquinolones/aminoglycosides** (high resistance rates)
- **Extended infusion** pip-tazo (4-hour infusion) may improve outcomes

## Sources

- [IDSA: HAP/VAP Guidelines 2024]
- [ATS: *Pseudomonas* Management 2023]

## Media

N/A
